Although different treatment options for MPN exist, including targeted therapy (Ruxolitinib or Jafaki, a drug that targets JAK2), chemotherapy, and immunotherapy, resistance to treatment inevitably occurs. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.